Granulomatosis with Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge

Joanna Wojciechowska · Wojciech Krajewski · Piotr Krajewski · Tomasz Kręcicki

1Department and Clinic of Otolaryngology-Head and Neck Surgery; 2Department of Urology, Wrocław Medical University, Wrocław, Poland

Granulomatosis with polyangiitis (GPA) is an idiopathic vasculitis of medium and small arteries, characterized by necrotizing granulomatous inflammation. GPA typically affects upper and lower respiratory tract with coexisting glomerulonephritis. This disease is generally characterized by antineutrophil cytoplasm antibodies (ANCA), nevertheless, there are rare cases with negative ANCA. GPA affects people at any age, with predominance of the sixth and seventh decade of life. In 80%–95% of the patients the first symptoms of GPA are otorhinolaryngological manifestations of head and neck including nose/sinuses, ears, eyes, larynx/trachea, oral cavity, and salivary glands. Diagnosis of GPA is based on Criteria of the American College of Rheumatology. In clinical practice diagnosis, the presence of distinctive ANCA antibodies and biopsy of affected organ are crucial. GPA must be differentiated from neoplastic, infectious or inflammatory ulcerative lesions of the head and neck. The standard treatment procedure is divided into two essential phases, induction and maintenance. The induction phase is based on combination of systemic corticosteroid and immunosuppressant therapy, whereas the maintenance phase comprises corticosteroids and azathioprine/methotrexate supplementation. Surgical treatment ought to be considered for patients who are not responding to pharmacotherapy.

Keywords: Granulomatosis with Polyangiitis; Wegener Granulomatosis; Otolaryngology

INTRODUCTION

Granulomatosis with polyangiitis (GPA), previously known as Wegener granulomatosis, is an idiopathic vasculitis of medium and small arteries, characterized by necrotizing granulomatous inflammation of the respiratory tract with coexisting glomerulonephritis. The estimated incidence of GPA in Europe is 5–10 cases per 1 million populations [1]. The GPA is a serious disease, mean survival time of untreated generalized GPA is 5 months due to renal or lung failure. Modern immunosuppressive treatments methods greatly improved patient outcomes and estimated median survival time to 21.7 years after diagnosis [2]. In the recent period of time, studies focusing on the suitability of biological agents in modifying the course of both systemic and localised disease have emerged. Spreading knowledge about this modern therapy in GPA among otolaryngologists may contribute to the improvement of prognosis.

GPA is generally characterized by antineutrophil cytoplasm antibodies (ANCA), although in rare cases of limited GPA, ANCA may not be present. As is was proven in in vitro studies ANCA activate neutrophils, enhance their adherence to endothelium, causing their degranulation and harming endothelial cells [3]. The disease affects people at any age, but the most common age of presentation of GPA is the sixth and seventh decade of life. Most often symptoms of GPA belong to classic triad of upper respiratory tract, lungs and kidneys, although any organ may be affected. In 80%–95% of the patients the first symptoms of GPA are otorhinolaryngological manifestations of head and neck [4]. In some cases otorhinolaryngological symptoms are sole sign of the disease and those forms, so-called “limited GPA” in contrast to more advanced stages with systemic vasculitis called “generalized GPA”. Limited GPA phenotype is often more recurrent and refractory and it is more likely to affect younger and more female population [5]. Generalized GPA typically includes renal and/or pulmonary involvement and systemic symptoms such as fever, asthenia, anorexia or weight loss are more probable [6]. Phenotypes of GPA differ from each oth-
er also in specific cytokine pattern. The limited form is characterized by Th1 lymphocyte polarization, as opposed to the generalized form with greater Th2 lymphocyte polarization [7]. During the course of GPA, the transformation from limited to generalized form and vice-versa is possible.

**DIAGNOSTICS**

According to Criteria of the American College of Rheumatology (ACR; 1990), GPA is diagnosed if 2 or more of the following 4 criteria are met: (1) sinus involvement; (2) lung X-ray showing nodules, a fixed pulmonary infiltrate or cavities; (3) urinary sediment with hematuria or red cell casts; and (4) histological granulomas within an artery or in the perivascular area of an artery or arteriole. The sensitivity and specificity of the ACR criteria are respectively 88.2% and 92.0% [8].

Currently in clinical diagnosis is usually based on presence of distinctive ANCA and biopsy of affected organ.

The main component of GPA diagnostics is serologic evaluation of cytoplasmic pattern of ANCA. ANCA, mainly of the IgG type, are targeted against proteinase 3 (cytoplasmic anti-neutrophil cytoplasmic antibody, c-ANCA) or myeloperoxidase (peri-nuclear- anti-neutrophil cytoplasmic antibody, p-ANCA). Both main neutrophil granule components. To determine level of ANCA immunofluorescence and enzyme-linked immunosorbent assay are used.

c-ANCA are specific for GPA, while p-ANCA are associated with inflammatory bowel disease, rheumatoid arthritis, autoimmune liver disease etc.

During flares the sensitivity and specificity of testing for c-ANCA are 91% and 99%, respectively [9]. In the generalized GPA, ANCA are elevated in 90%–95% of patients, whereas in the limited stage of GPA in the ear-nose-throat region, positive levels of c-ANCA may occur in only 46%–70% of patients [5,10].

Biopsy is usually used when ANCA testing is nondiagnostic or uncertain. In positive biopsies granulomatous inflammation including palisading granulomas, scattered giant cells, vasculitis or necrotizing granulomata can be found [11]. In localized disease, the role of the biopsy increases, because localized GPA has lower decisive predictive value of c-ANCA. In those patients biopsy should be performed to avoid oversight of c-ANCA negative GPA (10). Because up to 50% of specimens may be non-diagnostic, in some patients repeat biopsies are necessary [3].

Some findings on computed tomography (CT) scans like bone destruction of the nasal cavity, maxillary sinuses and mastoid air cells, as well as sclerosing osteitis and bony thickening in the same locations can be useful in diagnosis making [11]. GPA must be differentiated from neoplastic, infectious or inflammatory ulcerative lesions of the head and neck. GPA can be mistakenly taken for neoplasms as natural killer T-cell lymphoma or infections such as tuberculosis, aspergillosis and leishmaniasis, rarely occurring in our region leprosy, inflammatory conditions as sarcoidosis, and finally cocaine induced midline destructive lesions [12]. Other diagnoses that are also associated with the ANCA such as systemic lupus erythematosus (SLE), Churg-Strauss syndrome, microscopic polyangiitis and vasculitis induced by drug reactions, must be differentiated from GPA. To distinguish between those diseases some hints can be useful. SLE is associated with the presence of immune complex deposition and presence of anti-dsDNA or anti-Sm antibodies, which are not present in other potential diseases [13]. Drug reactions require history of various drugs use within 7 to 21 days of symptom onset. The biggest association was demonstrated for the propylthiouracil, but other drugs as methimazole, carbimazole, benzylthiouacil, hydralazine, anti-tumor necrosis factor-α (anti-TNF-α), sulfasalazine, D-penicillamine, and minocycline were described to induce vasculitis symptoms [14]. Microscopic polyangiitis in contrast to other diseases do not contain granulomas and Churg-Strauss syndrome include presence of asthma and eosinophilia, symptoms lacking in GPA [15].

**TREATMENT**

Treatment of GPA must be patient-adjusted. Adequate dosage of drugs should be administered to prevent severe side effects on the one hand, insufficient treatment with a risk of failure or early relapse on the other. The standard procedure is divided into two essential phases, induction and maintenance. The main goal of the first phase is rapid remission induction, which should last up to 6 months depending on clinical condition. The purpose of the second phase, which lasts 12–24 months, is to maintain remission and prevent aggravation of disease (Table 1) [16].

According to the current recommendations for generalized GPA the induction phase is based on combination of systemic corticosteroid and immunosuppressant therapy. Typical glucocorticoid therapy includes oral prednisone administration (starting dose of prednisone – 1 mg/kg/day with a maximum of 80 mg/day) with a dose reduction after 3–4 weeks. In severe cases oral therapy is preceded by intravenous bolus of methylprednisolone (7.5–15 mg/kg/day) administered for 1–3 days [11,17].

Cyclophosphamide (CYC) (alkylating agent) is common in first-line treatment (standard dose of CYC is 2 mg/kg/day or 600 mg/m²). CYC is used every 2 weeks for 1 month (at a dose of 600 mg/m²) and subsequently in appropriately modified dosage until achieving remission. Due to potential toxicity of cumulative dose during long-term exposure, dosage of CYC should be as low as possible [11,17].

Rituximab (RTX) (anti-CD20 monoclonal antibody) therapy should be additionally offered to patients with a relapse after complete cycle of CYC or when CYC is contraindicated. RTX should be given once a week at a dose of 375 mg/m² for a month. RTX allows lowering immunosuppressants exposure,
through reduction of CYC and glucocorticoid dose with few major adverse effects [18-20]. RTX should be preferred over CYC in premenopausal women whenever possible, because of the potential induction of infertility of CYC [21].

As it was proven single course of RTX was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months [22]. In recently published trials comparing CYC and RTX in remission induction authors demonstrated that RTX has an efficacy in remission induction comparable to that of CYC and is likely superior in relapsing patients [19,22-24].

In severe cases of GPA with pulmonary hemorrhage, plasma-exchange therapy combined with corticosteroid and immunosuppressant should be considered [25].

Other agents that have demonstrated effectiveness in small-scale studies are purine and pyrimidine antimetabolites, methotrexate, azathioprine (anti-proliferative agent), leflunomide (anti-proliferative agent), antithymocyte globulin (T-cell depletion antibody), and 15-deoxyspergualin (inhibitor of interleukin-2-stimulated maturation of T cells) [26].

Anti-TNF-α biological drugs have shown variable effectiveness in treatment of GPA, with positive effects of infliximab but no significant positive findings with etanercept (TNF inhibitor) [26,27]. Thus, etanercept should not be used as adjunct therapy.

Some reports suggest that intravenous immunoglobulin (IV Ig) can be considered when corticosteroids and CYC fail [28], however it was demonstrated that IV Ig, in comparison with the combination of steroids and immunosuppressants do not provide any therapeutic advantage in patients with GPA. Another drawback of IV Ig is its high price (one dose at 2 g/kg for a 70 kg patient = $8,400) [29].

Abatacept (inhibitor of CTLA-4 signals to T-cells) is proven to be associated with a high percentage of disease remission and prednisone discontinuation in GPA patients [30].

Severe GPA relapse should be treated just like initial GPA and other relapses should mean to restart maintenance therapy.

The maintenance phase, which is introduced after remission achievement, lasts up to 24 months and is based on oral corticosteroids and azathioprine/methotrexate supplementation. Discontinuation or use of low doses of maintenance therapy is associated with a higher relapse rate [31].

It was shown in some studies that methotrexate is safer than azathioprine, however both substances seem to be equivalent for maintenance therapy in patients with GPA after achieving remission [32].

In recently published MAINRITSAN trial it has been proven that RTX can be used as maintenance therapy as an alternative to azathioprine [33]. The results of more trials, especially on-going RITAZAREM and MAINRITSAN-2 are now keenly awaited to confirm those findings. Yet, current data support the use of RTX to maintain remission in patients at high risk of relapse or in patients who have experienced multiple relapses, or relapses

### Table 1. Drugs used in granulomatosis with polyangiitis therapy

| Drug                  | Phase of therapy | Drug action                        | Common adverse effects                                                                 |
|-----------------------|------------------|------------------------------------|----------------------------------------------------------------------------------------|
| Glucocorticoids       | Induction        | Anti-inflammatory and immunosuppressive agent | Weight gain, hyperglycemia, mood swings, easy bruising, infection risk, cataracts, hypertension, osteoporosis, Cushing syndrome |
| Cyclophosphamide      | Induction        | Alkylating agent                   | Cytopenias, nausea and vomiting, diarrhea, hair loss, teratogenesis (avoid in pregnancy), hemorrhagic cystitis, long-term risk of infertility, and malignancy |
| Rituximab             | Induction        | Anti-CD20 monoclonal antibody      | Infusion reactions neutropenia, hypogammaglobulinemia                                 |
|                       | Maintenance      |                                    | Infections (including small risk of progressive multifocal leukoencephalopathy)         |
|                       |                   |                                    | Potential for viral reactivation (e.g., hepatitis B)                                   |
|                       |                   |                                    | Development of other autoimmune conditions                                             |
| Plasmapheresis        | Induction        | Extracorporeal separation of blood components | Increased risk of sepsis especially if combined with cyclophosphamide |
|                       |                   |                                    | Potential risk of transmission of viral infection if using infected blood products    |
| Intravenous           | Induction        | Intravenous plasma protein (IgG)  | Potential risk of transmission of viral infection if using infected blood products    |
| Immunoglobulin        | Maintenance      | replacement therapy                | Allergic reaction in patients who are IgA deficient (due to expected levels of small amounts of IgA in the preparation) |
| Abatacept             | Induction        | Inhibitor of CTLA-4 signals to T cells | Headache, hypertension, nausea, liver dysfunctions, infections of upper respiratory tract |
| Methotrexate          | Maintenance      | Antimetabolite and antifolate agent | Nausea, diarrhea, mouth ulcers, hair loss, cytopenia, liver dysfunction               |
| Azathioprine          | Maintenance      | Purine analogue                    | Nausea, diarrhea, mouth ulcers, hair loss, cytopenia, liver dysfunction               |
|                       |                   |                                    | dysfunctions, nonmelanoma skin tumors (advise sun protection)                         |
| Belimumab             | Induction        | Anti-B-cell activating factor antibody | Bacterial infections, nausea, leucopenia, depression, insomnia                          |
|                       | Maintenance      |                                    |                                                                                      |

**Potential for viral reactivation (e.g., hepatitis B)**
while on alternative maintenance regimens. The optimal RTX
dosing schedule, however, remains to be determined [34]. Re-
results of RTX use in otolaryngology are generally good, however,
there are available studies showing GPA otolaryngological man-
ifestations endurance after RTX therapy [18,35].

The success of B-cell-depleting therapy with RTX in both in-
duction phase and maintenance phase of ANCA associated vas-
culitis has encouraged testing other B-cell-targeted therapies. Be-
limumab, anti B-cell activating factor antibody, has recently been
approved by U.S. Food and Drug Administration for the treat-
ment of SLE and is currently undergoing phase II/III clinical tri-
als in vasculitides [36].

In order to avoid Pneumocystis jiroveci infection, trimetoprim/ sulfamethoxazole should be given during whole immunosuppres-
sive therapy [17].

Surgical treatment ought to be considered for patients who
are not responding to pharmacotherapy. There is a wide variety
of procedures that patients may undergo including subglottic
stenosis dilation, endoscopic sinus surgery, mastoidectomy, dac-
ocystorhinostomy, myringotomy or rhinoplasty [11].

Nose and sinuses
Sinonasal involvement is the most common manifestation of GPA in the head and neck region, it occurs in up to 85% of pa-
tients, and over 25% of patients have only sinonasal symptoms
[4,10]. Tissue damage and bone destruction is caused by reduced
blood flow due to vasculitis. Sinusal involvement usually starts
in the septum area supplied by Kiesselbach plexus and then
spreads to the paranasal sinuses [37]. Clinical symptoms can
vary from inconsiderable nasal obstruction up to severe damage
of the structures of outer nose, paranasal sinuses and skull base.
However, the most frequent symptoms are nasal obstruction and
achoo. Reduction in the sense of smell or cacosmia may appear
as a result of purulent secretions associated with growth
of bacteria such as Pseudomonas aeruginosa or Staphylococ-
cus aureus [12]. Epiphora, other initial sign is caused by involve-
ment of the nasolacrimal duct [38]. Participation of the nasal
septum can cause perforations with whistling symptoms and in
the more advanced cases “saddle nose” deformity [39].

Perforations of nasal septum and their expansion can cause collapse of the cartilaginous midvault of the nose. Cartilages of
the nose change shape and orientation, which results in de-
pressed appearance of the nose, so-called saddle-nose deformity.
It deteriorates nasal obstruction and can cause anosmia.

Although that anterior septum supplied by Kiesselbach plexus
is the most frequent region of sinonasal GPA, any structure in
the sinonasal cavity, including mucosa, turbinates, septum, and
sinuses may be affected. For that reason there is an indication to
link both flexible endoscopy and CT scans in order to disclose
all potential lesions.

Treatment of sinonasal GPA is difficult. Standard pharmacol-
ogy or surgical interventions are often ineffective. To decrease the
incidence of sinonasal intensifications culture-directed antibiot-
ics followed by topical antibiotic irrigations can be helpful. Sa-
line high-flow irrigations are also useful as an additional therapy
to facilitate mucociliary clearance in affected nasal cavities.

Perforations of nasal septum are generally not treated [40]. Surgical management is not recommended due to poor tissue
perfusion, bad wound healing and possible infections. It is vital
in planning surgical treatment to identify an adequate period,
when GPA is in remission. It is also important to choose suitable
method of treatment that will have a chance of success in very
poor vascular framework. Anyhow, saddle nose deformity can
be successfully operated in the remission phase.

Eye
In some patients a granulomatous retro-orbital tumour can be
formed as primary granulation tissue in retro-orbital area or as
propagation of sinus lesions. In 2% of patients, GPA can appear
as secondary proptosis [41]. Ocular symptoms such as necrotiz-
ing nodular episcleritis, scleritis, corneal ulcerations, and retinal
vasculitis are also possible [42].

Ear
Otological manifestations can be found in 19%–61% of patients
with GPA [43]. Ear involvement may be the initial and only
symptom of GPA including external, middle and/or inner ear.
Implication of a middle ear is the most common form of otologi-
cal manifestation of GPA and it usually appears as unilateral or
bilateral chronic otitis media with serous effusion and conduc-
tive hearing loss. Typically, otitis media in GPA is secondary to
Eustachian tube dysfunction caused by nasopharyngeal involve-
ment [39]. Chronic mastoiditis can also occur in patients with
GPA. Facial nerve palsy with facial paralysis secondary to bone
destruction is possible, but rare [44,45].

External ear manifestations are seldom observed. Its involve-
ment can be described as erythematous or ulcerated lesions that
mimic perichondritis [12].

Inner ear involvement can cause sensorineuronal hearing loss in 5%–31% of patients with GPA. The possible causes of hear-
ing dysfunction include immunoology complexes situated in co-
chlea, vasculitis of the cochlea vessels or compression of the
vestibulocochlear nerve. Vertigo are quite rare, but possible con-
comitant symptom [39]. Hearing loss and vertigo may imitate Cogan syndrome (nonsyphilitic interstitial keratitis and bilateral
audiovestibular deficits), leading to improper diagnosis [43].

Middle ear effusions, resistant to systemic therapy, can be
managed with placement of a ventilation tube. Hearing amplifi-
cation devices may be considered in patients with hearing loss.

Salivary glands
Another rare manifestation of GPA can be involvement of the
large salivary glands. Parotid or submandibular glands may be
swollen and sore, symptoms may mimic malignancy [46].
Larynx and trachea
Laryngeal and/or tracheal manifestations, such as ulcers or subglottic stenosis are infrequent, but in some cases can be sole demonstration of GPA [47]. Subglottic stenosis may relate to 10%–20% of patients with GPA and is more likely to occur in childhood [11,43]. The main reason of subglottic stenosis is destruction of surrounding tissues due to vasculitis and reduced blood flow followed by their excessive reconstruction. Narrowing up to 75% of subglottic diameter usually remains asymptomatic, whereas strictures of at least 80% of larynx humen can be life threatening. Patients usually present dyspnea, wheezing or stridor. Cough and hoarseness are observed rarely. Patients with symptoms suggesting presence of subglottic stenosis should be examined with flexible endoscopy and CT imaging. These methods can reveal circumferential subglottic narrowing [12,43].
Choice of treatment method depends on patient’s clinical condition. In less advanced cases pharmacological treatment supported by topic inhaled glucocorticoids or optionally laser therapy can be sufficient. Despite pharmacotherapy up to 80% of patients have to undergo surgical interventions including transglottal injection of corticosteroids, endoscopic dilatation, radial laser incisions, stent placement, tracheostomy or resection of involved segment followed by reconstruction of missing section [12,43,48]. Any surgical procedure can lead to an aggravation of stenosis and for this reason it is recommended to initiate therapy with less invasive methods. However acute subglottic stenosis is life-threatening condition and often requires tracheotomy [49].
Supraglottic stenosis is a rare complication. So far, only one case has been reported in the literature [48].

Oral cavity
About 5%–10% patients with GPA experience at least one episode of pathological lesions in oral cavity in the course of the illness. Ulcerous changes may be localized on cheeks, tongue and palate. Another oral cavity manifestation is reddish colored irritating exophytic gingival swelling with petechial hemorrhages recalling strawberries [50]. In some cases it can be first symptom of GPA [51].

CONCLUSION
Otorhinolaryngologist is the first physician to contact for the majority of patients with GPA. This diagnosis must always be taken into consideration in patients with recurrent upper respiratory tract infections, otitis, mucosal ulcers and laryngitis. Proper and early diagnosis is crucial for imminent therapy implementation and allows avoiding irreversible organ damage. Studies, which appeared recently, create prospect for the introduction of less toxic and more effective treatment of GPA with biological agents.

CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.

REFERENCES
1. Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001 Dec;60(12):1156-7.
2. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000 May;43(5):1021-32.
3. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004 Jul;117(1):39-50.
4. Srouji IA, Andrews P, Edwards C, Lund VJ. Patterns of presentation and diagnosis of patients with Wegener’s granulomatosis: ENT aspects. J Laryngol Otol. 2007 Jul;121(7):653-8.
5. Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis. 2010 Nov;69(11):1934-9.
6. Stone JH; Wegener’s Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003 Aug;48(8):2299-309.
7. Csernok E, Trabandt A, Muller A, Wang GC, Moosig F, Pulsen J, et al. Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum. 1999 Apr;42(4):742-50.
8. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101-7.
9. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feusner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med. 1995 Dec;123(12):925-32.
10. Borner U, Landis BN, Banz Y, Villiger P, Ballini P, Caversaccio M, et al. Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy. 2012 Nov-Dec;26(6):475-80.
11. Erickson VR, Hwang PH. Wegener’s granulomatosis: current trends in diagnosis and management. Curr Opin Otolaryngol Head Neck Surg. 2007 Jun;15(3):170-6.
12. Trimarchi M, Sinico RA, Teggi R, Bussi M, Specks U, Meroni PL. Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev. 2013 Feb;12(4):501-5.
13. Falk RJ, Jennette JC. Wegener’s granulomatosis, systemic vasculitis, and antineutrophil cytoplasmic autoantibodies. Annu Rev Med. 1991 Feb;42:459-69.
14. Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012 Jan;70(1):12-7.
15. Mansi IA, Opran A, Rosner F. ANCA-associated small-vessel vasculitis. Am Fam Physician. 2002 Apr;65(8):1615-20.
16. Holle JU, Gross WL. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev. 2013 Feb;12(4):483-6.
17. Comarmond C, Cacont P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014 Nov;
34. Daikeler T, Kistler AD, Martin PY, Vogt B, Huynh-Do U. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). Swiss Med Wkly. 2015 Feb;145:w14103.

35. Malm I, Mener DJ, Kim J, Seo P, Kim YJ. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg. 2014 Jan;150(1):68-72.

36. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther. 2015 Jan;9:333-47.

37. Lloyd G, Lund VJ, Beale T, Howard D. Rhinologic changes in Wegener's granulomatosis. J Laryngol Otol. 2002 Jul;116(7):565-9.

38. Wong RJ, Gliklich RE, Rubin PA, Goodman M. Bilateral nasolacrimal duct obstruction managed with endoscopic techniques. Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):703-6.

39. Gottschlich S, Ambrosch P, Kramkowski D, Laudien M, Buchelt T, Gross WL, et al. Head and neck manifestations of Wegener's granulomatosis. Rhinology. 2006 Dec;44(4):227-33.

40. Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Otolaryngol. 2001 Jan;13(1):3-11.

41. Morales-Angulo C, Garcia-Zornoza R, Osebo-Aguera S, Calvo-Alen J, Gonzalez-Gay MA. Ear, nose and throat manifestations of Wegener's granulomatosis (granulomatosis with polyangiitis). Acta Otorrinolaringol Esp. 2012 May-Jun;63(3):206-11.

42. Choudhary MM, Hajj-Ali RA, Lowder CY. Gender and ocular manifestations of connective tissue diseases and systemic vasculitides. J Ophthalmol. 2014;2014:403042.

43. Alam DS, Seth R, Sindwani R, Woodson EA, Rajasekaran K. Upper airway manifestations of granulomatosis with polyangiitis. Clev Clin J Med. 2012 Nov;79 Suppl 3:S16-21.

44. McCaffrey TV, McDonald TJ, Facer GW, DeRemee RA. Otolologic manifestations of Wegener's granulomatosis. Otolaryngol Head Neck Surg. 1979;88(5):586-93.

45. Takagi D, Nakamari Y, Maguchi S, Furuta Y, Fukuda S. Otolologic manifestations of Wegener's granulomatosis. Laryngoscope. 2002 Sep;112(9):1684-90.

46. Specks U, Collby TV, Olsen KD, DeRemee RA. Salivary gland involvement in Wegener's granulomatosis. Arch Otolaryngol Head Neck Surg. 1991 Feb;117(2):218-23.

47. Daum TE, Specks U, Collby TV, Edell ES, Brulin MW, Prakash UB, et al. Tracheobronchial involvement in Wegener's granulomatosis. Ann Respir Crit Care Med. 1995 Feb;151(2 Pt 1):522-6.

48. Belloso A, Estrach C, Keith AO. Supraglottic stenosis in localized Wegener granulomatosis. Ear Nose Throat J. 2008 Jul;87(7):E11-4.

49. Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener's granulomatosis. Rheum Dis Clin North Am. 2007 Nov;33(4):755-75.

50. Knight JM, Hayduk MJ, Summerlin DJ, Mirowski GW. “Strawberry” gingival hyperplasia: a pathognomonic mucoctaneous finding in Wegener granulomatosis. Arch Dermatol. 2000 Feb;136(2):171-3.

51. Wawrzyńska K, Szczeklik K, Darczuk D, Lipska W, Szczeklik W, Musial J. Strawberry gingivitis as the first manifestation of granulomatosis with polyangiitis. Pol Arch Med Wewn. 2014;124(10):551-2.